IDRx developed precision cancer therapies designed to stop tumor escape mechanisms. GSK acquired the company in 2025 and now advances its lead KIT inhibitor, velzatinib, for GIST.
Products & media
Velzatinib (IDRX-42)
An investigational selective KIT tyrosine kinase inhibitor in clinical development for gastrointestinal stromal tumors across key KIT mutations.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Data current as of January 13, 2025
Leads
Participating Firms
Angels